Article
Use of <scp>JAK</scp> inhibitors in the management of myelofibrosis: a revision of the <scp>B</scp>ritish <scp>C</scp>ommittee for <scp>S</scp>tandards in <scp>H</scp>aematology <scp>G</scp>uidelines for <scp>I</scp>nvestigation and <scp>M</scp>anagement of <scp>M</scp>yelofibrosis 2012
25 Jun 2014
Abstract excerpt
The British Committee for Standards in Haematology (BCSH) Guidelines for myelofibrosis were produced in 2012 (Reilly et al, 2012), but since then Ruxolitinib, a JAK1/JAK2 inhibitor, has been approved for use in the European Union and highly prevalent mutations in the Calreticulin gene (CALR) have been described. We therefore wish to revise the existing guideline (Reilly et al, 2012) to accommodate this important...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.